SSY Group Gains NMPA Clearance for 1 ml:1 mg Cyanocobalamin Injection and Secures Second Consistency-Evaluation Approval

Bulletin Express05-07

SSY Group Limited announced that China’s National Medical Products Administration (NMPA) has approved two key milestones for the company’s Cyanocobalamin (Vitamin B12) Injection:

• Addition of a 1 ml:1 mg dosage specification. • Successful completion of the Quality and Efficacy Consistency Evaluation for generic drugs—marking the second such approval granted to a domestic entity for this product category.

Cyanocobalamin Injection is primarily indicated for megaloblastic anemia caused by intrinsic factor deficiency and can also serve as adjunctive therapy for subacute combined degenerative neurological disorders, including neuritis.

The Board issued the voluntary announcement on 7 May 2026 to keep shareholders and prospective investors informed of ongoing product-development progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144838627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144838627","market":"hk","top_or_hot":-1,"title":"SSY Group Gains NMPA Clearance for 1 ml:1 mg Cyanocobalamin Injection and Secures Second Consistency-Evaluation Approval","media":"Bulletin Express","content":"<p>SSY Group Limited announced that China’s National Medical Products Administration (NMPA) has approved two key milestones for the company’s Cyanocobalamin (Vitamin B12) Injection:</p>\n<p>• Addition of a 1 ml:1 mg dosage specification.  \n• Successful completion of the Quality and Efficacy Consistency Evaluation for generic drugs—marking the second such approval granted to a domestic entity for this product category.</p>\n<p>Cyanocobalamin Injection is primarily indicated for megaloblastic anemia caused by intrinsic factor deficiency and can also serve as adjunctive therapy for subacute combined degenerative neurological disorders, including neuritis.</p>\n<p>The Board issued the voluntary announcement on 7 May 2026 to keep shareholders and prospective investors informed of ongoing product-development progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Gains NMPA Clearance for 1 ml:1 mg Cyanocobalamin Injection and Secures Second Consistency-Evaluation Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Gains NMPA Clearance for 1 ml:1 mg Cyanocobalamin Injection and Secures Second Consistency-Evaluation Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-07 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY Group Limited announced that China’s National Medical Products Administration (NMPA) has approved two key milestones for the company’s Cyanocobalamin (Vitamin B12) Injection:</p>\n<p>• Addition of a 1 ml:1 mg dosage specification.  \n• Successful completion of the Quality and Efficacy Consistency Evaluation for generic drugs—marking the second such approval granted to a domestic entity for this product category.</p>\n<p>Cyanocobalamin Injection is primarily indicated for megaloblastic anemia caused by intrinsic factor deficiency and can also serve as adjunctive therapy for subacute combined degenerative neurological disorders, including neuritis.</p>\n<p>The Board issued the voluntary announcement on 7 May 2026 to keep shareholders and prospective investors informed of ongoing product-development progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"","article_id":"1144838627","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144838627","pubTimestamp":1778143482,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"SSY Group Limited announced that China’s National Medical Products Administration (NMPA) has approved two key milestones for the company’s Cyanocobalamin (Vitamin B12) Injection: • Addition of a 1...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02005":"石四药集团"},"translate_title":"SSY集团1mL：1mg氰钴胺注射液获NMPA批准并获得第二个一致性评价批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY Group Limited announced that China’s National Medical Products Administration (NMPA) has approved two key milestones for the company’s Cyanocobalamin (Vitamin B12) Injection:\n• Addition of a 1 ml:1 mg dosage specification.  \n• Successful completion of the Quality and Efficacy Consistency Evaluation for generic drugs—marking the second such approval granted to a domestic entity for this product category.\nCyanocobalamin Injection is primarily indicated for megaloblastic anemia caused by intrinsic factor deficiency and can also serve as adjunctive therapy for subacute combined degenerative neurological disorders, including neuritis.\nThe Board issued the voluntary announcement on 7 May 2026 to keep shareholders and prospective investors informed of ongoing product-development progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144838627","isCrawlerRequest":true}